Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Running, not enrolling · Phase 3

Conditions studied: B-cell Malignancies

In brief

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.

Key facts

Study ID
NCT04170283
Run by
BeiGene
People needed
955
Starts
2020-01-16
Expected to finish
2028-12-01
Last updated by the study team
2025-10-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.